文献速递泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤

淋巴结阳性子宫内膜样癌辅助放疗野范围与失败部位

Adjuvant Radiation Field Extent and Sites of Failure in Node Positive Endometrioid Endometrial Cancer.
PubMed 文献 · Pract Radiat Oncol · 2021-05-18

多机构回顾性研究分析143例FIGO IIIC期子宫内膜样癌患者,比较盆腔放疗与扩大野放疗的生存结局和失败部位。中位随访59个月,5年无复发生存率和总生存率分别为73%和87%。盆腔放疗后孤立腹主动脉旁淋巴结复发少见且可 salvage 治疗。

要点

  • 盆腔放疗后野外孤立腹主动脉旁淋巴结复发5例(6%),其中3例长期生存。
  • 腹主动脉旁复发者中86%有淋巴血管间隙浸润,71%肌层浸润≥50%。

核心结论

  • 辅助放化疗为FIGO IIIC期子宫内膜样癌带来良好生存结局。
  • 盆腔淋巴结阳性患者中,盆腔放疗野外孤立腹主动脉旁复发不常见且适合 salvage 治疗。

研究设计与样本

  • 多机构回顾性研究纳入2000至2016年143例FIGO IIIC1或IIIC2期子宫内膜样癌接受辅助放疗的患者。
  • 按亚期和放疗野范围分组:IIIC1接受扩大野放疗、IIIC1接受盆腔放疗、IIIC2接受扩大野放疗。

主要发现

  • 中位随访59个月,87%患者接受化疗,5年RFS和OS分别为73%和87%。
  • 野内阴道复发2例(1%),野内淋巴结复发4例(3%)。
  • 78例IIIC1盆腔放疗患者中5例(6%)出现野外孤立腹主动脉旁淋巴结复发,3例 salvage 后生存超过6年。

关键数值与推荐

  • 腹主动脉旁复发患者中86%有淋巴血管间隙浸润,71%肌层浸润≥50%,57%为3级。

临床怎么用

  • 对IIIC1期子宫内膜样癌,盆腔放疗联合化疗是可接受的辅助策略,需关注野外腹主动脉旁复发风险。
  • 具有淋巴血管间隙浸润、深肌层浸润或3级病变的患者应加强腹主动脉旁淋巴结监测。

局限性

  • 回顾性研究设计,样本量143例,亚组比较可能受混杂因素影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: In patients with node-positive endometrial cancer, adjuvant radiation therapy with chemotherapy decreases local-regional recurrence compared with chemotherapy alone. However, the optimal radiation field borders and extent of nodal coverage have not been well studied. In a multi-institutional cohort, survival outcomes and sites of failure were analyzed for patients with International Federation of Gynaecology and Obstetrics (FIGO) stage IIIC endometrioid endometrial cancer treated with pelvic radiation therapy (PRT) versus extended-field radiation therapy (EFRT), which encompassed high para-aortic lymph nodes. METHODS AND MATERIALS: In a multi-institutional retrospective study, 143 patients with FIGO stage IIIC1 or IIIC2 endometrioid endometrial cancer treated with adjuvant radiation therapy from 2000 to 2016 were identified. Patient subgroups were classified by substage and radiation field extent: stage IIIC1 received EFRT, stage IIIC1 received PRT, and stage IIIC2 received EFRT. Recurrence-free survival (RFS), overall survival (OS), and out-of-field recurrence were calculated by the Kaplan-Meier method. Multivariate analysis was performed using the Cox proportional hazards model. Sites of failure were categorized as within or outside the radiation field. RESULTS: The median follow-up was 59 months; 87% of patients received chemotherapy. The 5-year RFS and OS rates were 73% and 87%, respectively. By subgroup, 5-year RFS rates were 79% for stage IIIC1 EFRT, 73% for stage IIIC1 PRT, and 69% for stage IIIC2 EFRT (P = .4). On multivariate analysis, the recurrence risk was highest for stage IIIC2 EFRT, although this result was not statistically significant (adjusted hazard ratio, 2.0; P = .4). In-field vaginal and nodal recurrences were observed in 2 patients (1%) and 4 patients (3%), respectively. Of 78 patients with stage IIIC1 cancer treated with PRT, 5 (6%) had isolated para-aortic nodal relapse outside the radiation field; 3 were long-term survivors (more than 6 years after salvage therapy). For patients with para-aortic recurrence, 86% had lymphovascular invasion, 71% had myometrial invasion of ≥50%, and 57% had grade 3 disease. CONCLUSIONS: Adjuvant chemoradiation therapy resulted in excellent survival outcomes for patients with FIGO stage IIIC endometrioid endometrial cancer. For patients with positive pelvic nodes, isolated para-aortic relapse outside the PRT field was uncommon and amenable to salvage therapy.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Yerramilli D, Chen YH, Venkatachalam V, et al. Adjuvant Radiation Field Extent and Sites of Failure in Node Positive Endometrioid Endometrial Cancer. Pract Radiat Oncol. 2021. PMID: 34015544. doi:10.1016/j.prro.2021.04.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。